论文部分内容阅读
目的:探讨TEC化疗方案治疗术后三阴性乳腺癌的临床疗效。方法:对接受6个周期TEC化疗方案治疗的36例三阴性乳腺癌进行回顾性研究,分析近远期化疗疗效。结果:化疗后随访18~24个月,中位22.8个月;36例患者中30例未出现局部复发和远处转移,总有效率为83.33%。主要不良反应包括中性粒细胞减少31例(86.11%),中性粒细胞减少性发热3例(8.33%),恶心、呕吐30例(83.33%),腹泻8例(22.22%),口腔黏膜炎5例(13.89%),乏力虚弱22例(61.11%),术后死亡1例,局部复发3例,远处转移2例,2年生存率为97.22%。结论:对三阴性乳腺癌(TNBC)在早期给予正确有效的治疗可显著提高患者的生存率,而目前蒽环联合紫杉醇的TEC辅助化疗有利于提高TNBC术后治疗效果,在改善患者的生活质量、提高患者生存率等方面也发挥着不可低估的作用和意义。
Objective: To investigate the clinical efficacy of TEC chemotherapy in the treatment of postoperative triple negative breast cancer. Methods: A retrospective study was performed on 36 cases of triple negative breast cancer treated with 6 cycles of chemotherapy regimen of TEC, and the effect of chemotherapy in the near and distant phases was analyzed. Results: All the patients were followed up 18 to 24 months after chemotherapy. The median time was 22.8 months. No local recurrence or distant metastasis was found in 30 of 36 patients. The total effective rate was 83.33%. The main adverse reactions included neutropenia in 31 patients (86.11%), neutropenic fever in 3 patients (8.33%), nausea and vomiting in 30 patients (83.33%), diarrhea in 8 patients (22.22%), oral mucosa There were 5 cases of inflammation (13.89%), weakness and weakness in 22 cases (61.11%), postoperative death in 1 case, local recurrence in 3 cases, distant metastasis in 2 cases and 2-year survival rate of 97.22%. Conclusions: Correct and effective treatment of triple negative breast cancer (TNBC) in the early stage can significantly improve the survival rate of patients. Currently, TEC adjuvant chemotherapy with anthracycline combined with paclitaxel is beneficial to improve postoperative TNBC treatment and improve the quality of life of patients , Improve patient survival and other aspects also play a role and significance can not be underestimated.